{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:43:48Z","timestamp":1792122228824,"version":"4.4.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Second Century Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s00277-025-06524-6","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T09:07:17Z","timestamp":1757408837000},"page":"4791-4809","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Comparative efficacy and safety of BCMA-targeted CAR T cells and BiTEs in relapsed\/refractory multiple myeloma: a meta-analysis of interventional and real-world studies"],"prefix":"10.1007","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8372-4868","authenticated-orcid":false,"given":"Pisanupong","family":"Techaapornkun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4331-3546","authenticated-orcid":false,"given":"Waranyoo","family":"Rojpalakorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4051-3578","authenticated-orcid":false,"given":"Nuthchaya","family":"Mejun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2801-7794","authenticated-orcid":false,"given":"Asmita","family":"Khaniya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0482-4176","authenticated-orcid":false,"given":"Arsa","family":"Thammahong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6759-6003","authenticated-orcid":false,"given":"May Soe","family":"Thu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2224-6856","authenticated-orcid":false,"given":"Nattiya","family":"Hirankarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8840-0433","authenticated-orcid":false,"given":"Palada","family":"Pitakkitnukun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"key":"6524_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103504","volume":"168","author":"S Kiss","year":"2021","unstructured":"Kiss S, Gede N, So\u00f3s A, Hegyi P, Nagy B, Imrei M et al (2021) Efficacy of first-line treatment options in transplant-ineligible multiple myeloma: a network meta-analysis. Crit Rev Oncol Hematol 168:103504","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"6524_CR2","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/ajh.25791","volume":"95","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar SV (2020) Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol 95(5):548\u2013567","journal-title":"Am J Hematol"},{"issue":"7","key":"6524_CR3","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s11912-019-0804-4","volume":"21","author":"C Antoine-Pepeljugoski","year":"2019","unstructured":"Antoine-Pepeljugoski C, Braunstein MJ (2019) Management of newly diagnosed elderly multiple myeloma patients. Curr Oncol Rep 21(7):64","journal-title":"Curr Oncol Rep"},{"key":"6524_CR4","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.ejca.2018.07.005","volume":"103","author":"J Ferlay","year":"2018","unstructured":"Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M et al (2018) Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 103:356\u2013387","journal-title":"Eur J Cancer"},{"key":"6524_CR5","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.critrevonc.2019.02.011","volume":"137","author":"MA Fraz","year":"2019","unstructured":"Fraz MA, Warraich FH, Warraich SU, Tariq MJ, Warraich Z, Khan AY et al (2019) Special considerations for the treatment of multiple myeloma according to advanced age, comorbidities, frailty and organ dysfunction. Crit Rev Oncol Hematol 137:18\u201326","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"6524_CR6","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s40265-017-0689-1","volume":"77","author":"SA Holstein","year":"2017","unstructured":"Holstein SA, McCarthy PL (2017) Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience. Drugs 77(5):505\u2013520","journal-title":"Drugs"},{"key":"6524_CR7","doi-asserted-by":"crossref","unstructured":"Cellular Therapies for Multiple Myeloma Engineering Hope [Internet]. [cited 2025 Mar 7]. Available from: https:\/\/www.mdpi.com\/2072-6694\/16\/22\/3867","DOI":"10.3390\/cancers16223867"},{"issue":"4","key":"6524_CR8","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3324\/haematol.2015.129189","volume":"101","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld P, Broijl A (2016) Treatment of relapsed and refractory multiple myeloma. Haematologica 101(4):396\u2013406","journal-title":"Haematologica"},{"issue":"7","key":"6524_CR9","doi-asserted-by":"publisher","first-page":"4464","DOI":"10.3390\/curroncol29070355","volume":"29","author":"ME Stalker","year":"2022","unstructured":"Stalker ME, Mark TM (2022) Clinical management of triple-class refractory multiple myeloma: a review of current strategies and emerging therapies. Curr Oncol 29(7):4464\u20134477","journal-title":"Curr Oncol"},{"issue":"11","key":"6524_CR10","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1634\/theoncologist.2016-0104","volume":"21","author":"S Usmani","year":"2016","unstructured":"Usmani S, Ahmadi T, Ng Y, Lam A, Desai A, Potluri R et al (2016) Analysis of real-world data on overall survival in multiple myeloma patients with \u2265 3 prior lines of therapy including a proteasome inhibitor (PI) and an Immunomodulatory drug (IMiD), or double refractory to a PI and an imid. Oncologist 21(11):1355\u20131361","journal-title":"Oncologist"},{"key":"6524_CR11","doi-asserted-by":"publisher","unstructured":"Cho SF, Anderson KC, Tai YT (2018) Targeting B Cell Maturation Antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy. Front Immunol [Internet]. [cited 2025 Mar 31];9. Available from: https:\/\/www.frontiersin.org\/journals\/immunology\/articles\/https:\/\/doi.org\/10.3389\/fimmu.2018.01821\/full","DOI":"10.3389\/fimmu.2018.01821\/full"},{"key":"6524_CR12","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","volume":"13","author":"B Yu","year":"2020","unstructured":"Yu B, Jiang T, Liu D (2020) BCMA-targeted immunotherapy for multiple myeloma. J Hematol OncolJ Hematol Oncol 13:125","journal-title":"J Hematol OncolJ Hematol Oncol"},{"issue":"1","key":"6524_CR13","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1084\/jem.20031330","volume":"199","author":"BP O\u2019Connor","year":"2004","unstructured":"O\u2019Connor BP, Raman VS, Erickson LD, Cook WJ, Weaver LK, Ahonen C et al (2004) BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 199(1):91\u201398","journal-title":"J Exp Med"},{"issue":"6","key":"6524_CR14","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/bjh.14145","volume":"174","author":"L Lee","year":"2016","unstructured":"Lee L, Bounds D, Paterson J, Herledan G, Sully K, Seestaller-Wehr LM et al (2016) Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma. Br J Haematol 174(6):911\u2013922","journal-title":"Br J Haematol"},{"issue":"1","key":"6524_CR15","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13045-019-0758-x","volume":"12","author":"J Wei","year":"2019","unstructured":"Wei J, Han X, Bo J, Han W (2019) Target selection for CAR-T therapy. J Hematol OncolJ Hematol Oncol 12(1):62","journal-title":"J Hematol OncolJ Hematol Oncol"},{"issue":"3","key":"6524_CR16","doi-asserted-by":"publisher","first-page":"e432204","DOI":"10.1200\/EDBK_432204","volume":"44","author":"M Mohan","year":"2024","unstructured":"Mohan M, Van Oekelen O, Akhtar OS, Cohen A, Parekh S (2024) Charting the course: sequencing immunotherapy for multiple myeloma. Am Soc Clin Oncol Educ Book 44(3):e432204","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"6","key":"6524_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061283","volume":"20","author":"MR Benmebarek","year":"2019","unstructured":"Benmebarek MR, Karches CH, Cadilha BL, Lesch S, Endres S, Kobold S (2019) Killing mechanisms of chimeric antigen receptor (CAR) T cells. Int J Mol Sci 20(6):1283","journal-title":"Int J Mol Sci"},{"key":"6524_CR18","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ymeth.2018.10.026","volume":"154","author":"D Ellerman","year":"2019","unstructured":"Ellerman D (2019) Bispecific T-cell engagers: towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety. Methods San Diego Calif 154:102\u2013117","journal-title":"Methods San Diego Calif"},{"issue":"4","key":"6524_CR19","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV et al (2023) Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med 389(4):335\u2013347","journal-title":"N Engl J Med"},{"issue":"11","key":"6524_CR20","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK et al (2023) Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med 388(11):1002\u20131014","journal-title":"N Engl J Med"},{"issue":"11","key":"6524_CR21","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1200\/JCO.22.01365","volume":"41","author":"DK Hansen","year":"2023","unstructured":"Hansen DK, Sidana S, Peres LC, Colin Leitzinger C, Shune L, Shrewsbury A et al (2023) Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium. J Clin Oncol 41(11):2087\u20132097","journal-title":"J Clin Oncol"},{"issue":"7","key":"6524_CR22","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.3390\/cancers15072160","volume":"15","author":"D Dima","year":"2023","unstructured":"Dima D, Ullah F, Mazzoni S, Williams L, Faiman B, Kurkowski A et al (2023) Management of relapsed-refractory multiple myeloma in the era of advanced therapies: evidence-based recommendations for routine clinical practice. Cancers (Basel) 15(7):2160","journal-title":"Cancers (Basel)"},{"issue":"8","key":"6524_CR23","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P et al (2016) International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17(8):e328\u2013e346","journal-title":"Lancet Oncol"},{"issue":"6","key":"6524_CR24","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, Van De Donk NWCJ, Nahi H, San-Miguel JF, Oriol A et al (2022) Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 387(6):495\u2013505","journal-title":"N Engl J Med"},{"issue":"9","key":"6524_CR25","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R et al (2023) Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med 29(9):2259\u20132267","journal-title":"Nat Med"},{"issue":"1","key":"6524_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-024-01191-8","volume":"14","author":"D Swan","year":"2024","unstructured":"Swan D, Madduri D, Hocking J (2024) CAR-T cell therapy in multiple myeloma: current status and future challenges. Blood Cancer J 14(1):1\u201316","journal-title":"Blood Cancer J"},{"issue":"5","key":"6524_CR27","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/ajh.26486","volume":"97","author":"X Shi","year":"2022","unstructured":"Shi X, Yan L, Shang J, Kang L, Yan Z, Jin S et al (2022) Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma. Am J Hematol 97(5):537\u2013547","journal-title":"Am J Hematol"},{"issue":"Suppl","key":"6524_CR28","doi-asserted-by":"publisher","first-page":"e84060bf","DOI":"10.1097\/01.HS9.0000970380.84060.bf","volume":"7","author":"J Du","year":"2023","unstructured":"Du J, Fu W, Jiang H, Dong B, Gao L, Liu L et al (2023) P869: UPDATED RESULTS OF A PHASE I, OPEN-LABEL STUDY OF BCMA\/CD19 DUAL-TARGETING FASTCAR-T GC012F FOR PATIENTS WITH RELAPSED\/REFRACTORY MULTIPLE MYELOMA (RRMM). HemaSphere 7(Suppl):e84060bf","journal-title":"HemaSphere"},{"key":"6524_CR29","unstructured":"FDA\u2019s Recent Approval of 2 CAR T-Cell Therapies a \u2018Big Step Toward\u2019 Long-Term Control of Myeloma for More Patients | Leukemia and Lymphoma Society [Internet]. 2025 [cited 2025 Apr 3]. Available from: https:\/\/www.lls.org\/news\/fdas-recent-approval-2-car-t-cell-therapies-big-step-toward-long-term-control-myeloma-more"},{"issue":"11","key":"6524_CR30","doi-asserted-by":"publisher","first-page":"e010064","DOI":"10.1136\/jitc-2024-010064","volume":"12","author":"X Liang","year":"2024","unstructured":"Liang X, Wang Y, Luo B, Lin B, Lu W, Tian S et al (2024) Comparison of CAR T-cell and bispecific antibody as third-line or later-line treatments for multiple myeloma: a meta-analysis. J Immunother Cancer 12(11):e010064","journal-title":"J Immunother Cancer"},{"issue":"4","key":"6524_CR31","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN et al (2019) ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biology of Blood and Marrow Transplantation 25(4):625\u2013638","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"6524_CR32","doi-asserted-by":"publisher","first-page":"n160","DOI":"10.1136\/bmj.n160","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ 372:n160","journal-title":"BMJ"},{"key":"6524_CR33","first-page":"359","volume":"2006","author":"X Huang","year":"2006","unstructured":"Huang X, Lin J, Demner-Fushman D (2006) Evaluation of PICO as a knowledge representation for clinical questions. AMIA Annu Symp Proc AMIA Symp 2006:359\u2013363","journal-title":"AMIA Annu Symp Proc AMIA Symp"},{"issue":"Pt 1","key":"6524_CR34","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.envint.2018.07.015","volume":"121","author":"RL Morgan","year":"2018","unstructured":"Morgan RL, Whaley P, Thayer KA, Sch\u00fcnemann HJ (2018) Identifying the PECO: a framework for formulating good questions to explore the association of environmental and other exposures with health outcomes. Environ Int 121(Pt 1):1027\u20131031","journal-title":"Environ Int"},{"key":"6524_CR35","unstructured":"Covidence. Covidence [Internet]. Veritas Health Innovation (2024) Available from: https:\/\/www.covidence.org"},{"key":"6524_CR36","unstructured":"Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J Originalarticle methodological index for non-randomized studies (minors)"},{"key":"6524_CR37","first-page":"69","volume":"11","author":"LK Smith","year":"2019","unstructured":"Smith LK, Dures E, Beswick A (2019) Systematic review of the clinical effectiveness for long-term follow-up of total hip arthroplasty. Orthop Res Rev 11:69\u201378","journal-title":"Orthop Res Rev"},{"issue":"3","key":"6524_CR38","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177\u2013188","journal-title":"Control Clin Trials"},{"issue":"12","key":"6524_CR39","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1111\/cas.15556","volume":"113","author":"M Ri","year":"2022","unstructured":"Ri M, Suzuki K, Ishida T, Kuroda J, Tsukamoto T, Teshima T et al (2022) Ciltacabtagene autoleucel in patients with relapsed\/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort. Cancer Sci 113(12):4267\u20134276","journal-title":"Cancer Sci"},{"issue":"8","key":"6524_CR40","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S et al (2021) Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med 384(8):705\u2013716","journal-title":"N Engl J Med"},{"issue":"5","key":"6524_CR41","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s12185-023-03538-6","volume":"117","author":"D Minakata","year":"2023","unstructured":"Minakata D, Ishida T, Ando K, Suzuki R, Tanaka J, Hagiwara S et al (2023) Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma. Int J Hematol 117(5):729\u2013737","journal-title":"Int J Hematol"},{"issue":"6","key":"6524_CR42","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1080\/10428194.2022.2030476","volume":"63","author":"H Zhang","year":"2022","unstructured":"Zhang H, Liu M, Xiao X, Lv H, Jiang Y, Li X et al (2022) A combination of humanized anti-BCMA and murine anti-CD38 CAR-T cell therapy in patients with relapsed or refractory multiple myeloma. Leuk Lymphoma 63(6):1418\u20131427","journal-title":"Leuk Lymphoma"},{"issue":"20","key":"6524_CR43","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1200\/JCO.21.01676","volume":"40","author":"Y Wang","year":"2022","unstructured":"Wang Y, Cao J, Gu W, Shi M, Lan J, Yan Z et al (2022) Long-term follow-up of combination of B-cell maturation antigen and CD19 chimeric antigen receptor T cells in multiple myeloma. J Clin Oncol 40(20):2246\u20132256","journal-title":"J Clin Oncol"},{"issue":"6","key":"6524_CR44","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.22.00690","volume":"41","author":"JQ Mi","year":"2023","unstructured":"Mi JQ, Zhao W, Jing H, Fu W, Hu J, Chen L et al (2023) Phase II, open-label study of ciltacabtagene autoleucel, an anti\u2013B-cell maturation antigen chimeric antigen receptor\u2013T-cell therapy, in Chinese patients with relapsed\/refractory multiple myeloma (CARTIFAN-1). J Clin Oncol 41(6):1275\u20131284","journal-title":"J Clin Oncol"},{"issue":"10297","key":"6524_CR45","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD et al (2021) Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 398(10297):314\u2013324","journal-title":"Lancet"},{"issue":"7","key":"6524_CR46","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1002\/ajh.26583","volume":"97","author":"J Du","year":"2022","unstructured":"Du J, Wei R, Jiang S, Jiang H, Li L, Qiang W et al (2022) <scp>CAR\u2010T<\/scp>cell therapy targeting B cell maturation antigen is effective for relapsed\/refractory multiple myeloma, including cases with poor performance status. Am J Hematol 97(7):933\u2013941","journal-title":"Am J Hematol"},{"issue":"1","key":"6524_CR47","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41375-023-02065-x","volume":"38","author":"C Li","year":"2024","unstructured":"Li C, Xu J, Luo W, Liao D, Xie W, Wei Q et al (2024) Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma. Leukemia 38(1):149\u2013159","journal-title":"Leukemia"},{"issue":"15","key":"6524_CR48","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1182\/bloodadvances.2024012967","volume":"8","author":"S Kfir-Erenfeld","year":"2024","unstructured":"Kfir-Erenfeld S, Asherie N, Lebel E, Vainstein V, Assayag M, Dubnikov Sharon T et al (2024) Clinical evaluation and determinants of response to HBI0101 (BCMA CART) therapy in relapsed\/refractory multiple myeloma. Blood Adv 8(15):4077\u20134088","journal-title":"Blood Adv"},{"issue":"22","key":"6524_CR49","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1200\/JCO.24.01008","volume":"42","author":"N Bumma","year":"2024","unstructured":"Bumma N, Richter J, Jagannath S, Lee HC, Hoffman JE, Suvannasankha A et al (2024) Linvoseltamab for treatment of relapsed\/refractory multiple myeloma. J Clin Oncol 42(22):2702\u20132712","journal-title":"J Clin Oncol"},{"issue":"13","key":"6524_CR50","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1182\/bloodadvances.2024012773","volume":"8","author":"B Puertas","year":"2024","unstructured":"Puertas B, Fern\u00e1ndez-S\u00e1nchez A, Alejo E, Rey-B\u00faa B, Mart\u00edn-L\u00f3pez AA, P\u00e9rez-L\u00f3pez E et al (2024) A research center\u2019s experience of T-cell\u2013redirecting therapies in triple-class refractory multiple myeloma. Blood Adv 8(13):3478\u20133487","journal-title":"Blood Adv"},{"issue":"3","key":"6524_CR51","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1111\/bjh.19244","volume":"204","author":"L Hammons","year":"2024","unstructured":"Hammons L, Haider S, Portuguese AJ, Banerjee R, Szabo A, Pasquini M et al (2024) Chimeric antigen receptor and bispecific T-cell engager therapies in multiple myeloma patients with prior allogeneic transplantation. Br J Haematol 204(3):887\u2013891","journal-title":"Br J Haematol"},{"issue":"23","key":"6524_CR52","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood.2023023616","volume":"144","author":"C Touzeau","year":"2024","unstructured":"Touzeau C, Krishnan AY, Moreau P, Perrot A, Usmani SZ, Manier S et al (2024) Efficacy and safety of teclistamab in patients with relapsed\/refractory multiple myeloma after BCMA-targeting therapies. Blood 144(23):2375\u20132388","journal-title":"Blood"},{"issue":"1","key":"6524_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-023-00886-8","volume":"13","author":"CJ Ferreri","year":"2023","unstructured":"Ferreri CJ, Hildebrandt MAT, Hashmi H, Shune LO, McGuirk JP, Sborov DW et al (2023) Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. Blood Cancer J 13(1):1\u20139","journal-title":"Blood Cancer J"},{"issue":"17","key":"6524_CR54","doi-asserted-by":"publisher","first-page":"4679","DOI":"10.1182\/bloodadvances.2024013540","volume":"8","author":"NM Kalariya","year":"2024","unstructured":"Kalariya NM, Hildebrandt MAT, Hansen DK, Sidana S, Khouri J, Ferreri CJ et al (2024) Clinical outcomes after idecabtagene vicleucel in older patients with multiple myeloma: a multicenter real-world experience. Blood Adv 8(17):4679\u20134688","journal-title":"Blood Adv"},{"issue":"6","key":"6524_CR55","first-page":"350","volume":"29","author":"KR Reyes","year":"2023","unstructured":"Reyes KR, Huang CY, Lo M, Arora S, Chung A, Wong SW et al (2023) Safety and efficacy of BCMA CAR-T cell therapy in older patients with multiple myeloma. Transpl Cell Ther 29(6):350\u2013355","journal-title":"Transpl Cell Ther"},{"issue":"4","key":"6524_CR56","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","volume":"34","author":"N Shah","year":"2020","unstructured":"Shah N, Chari A, Scott E, Mezzi K, Usmani SZ (2020) B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia 34(4):985\u20131005","journal-title":"Leukemia"},{"issue":"5","key":"6524_CR57","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1080\/14712598.2024.2352591","volume":"24","author":"S Jagannath","year":"2024","unstructured":"Jagannath S, Jackson CC, Schecter JM, Lendvai N, Sun H, Akram M et al (2024) Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma. Expert Opin Biol Ther 24(5):339\u2013350","journal-title":"Expert Opin Biol Ther"},{"key":"6524_CR58","unstructured":"AJMC [Internet] (2024) [cited 2025 Mar 28]. Ide-cel receives approval for earlier treatment for relapsed, refractory multiple myeloma. Available from: https:\/\/www.ajmc.com\/view\/ide-cel-receives-approval-for-earlier-treatment-for-relapsed-refractory-multiple-myeloma"},{"issue":"1","key":"6524_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-024-01102-x","volume":"14","author":"J Martinez-Lopez","year":"2024","unstructured":"Martinez-Lopez J, Lopez-Mu\u00f1oz N, Chari A, Dorado S, Barrio S, Arora S et al (2024) Measurable residual disease (MRD) dynamics in multiple myeloma and the influence of clonal diversity analyzed by artificial intelligence. Blood Cancer J 14(1):1\u20136","journal-title":"Blood Cancer J"},{"issue":"23","key":"6524_CR60","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1182\/blood.2022016170","volume":"140","author":"B Paiva","year":"2022","unstructured":"Paiva B, San-Miguel J, Avet-Loiseau H (2022) MRD in multiple myeloma: does CR really matter? Blood 140(23):2423\u20132428","journal-title":"Blood"},{"key":"6524_CR61","unstructured":"International Myeloma Foundation [Internet] [cited 2025 Apr 10]. MRD and Mass spectrometry testing. Available from: https:\/\/www.myeloma.org\/mrd-mass-spectrometry-testing"},{"issue":"1","key":"6524_CR62","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41408-024-01043-5","volume":"14","author":"K Nath","year":"2024","unstructured":"Nath K, Shekarkhand T, Nemirovsky D, Derkach A, Costa BA, Nishimura N et al (2024) Comparison of infectious complications with BCMA-directed therapies in multiple myeloma. Blood Cancer J 14(1):88","journal-title":"Blood Cancer J"},{"issue":"11","key":"6524_CR63","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.3324\/haematol.2023.283003","volume":"108","author":"B Palmen","year":"2023","unstructured":"Palmen B, Hari P, D\u2019Souza A, Abid MB (2023) Protracted viral infections in patients with multiple myeloma receiving bispecific T-cell engager therapy targeting B-cell maturation antigen. Haematologica 108(11):3186\u20133190","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"6524_CR64","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1182\/blood-2023-179413","volume":"142","author":"K Nath","year":"2023","unstructured":"Nath K, Shekarkhand T, Costa BA, Nemirovsky D, Derkach A, Nishimura N et al (2023) A comparative analysis of infectious complications in patients with multiple myeloma treated with BCMA-targeted bispecific antibodies and CAR T-cell therapy. Blood 142(Supplement 1):1957\u20131957","journal-title":"Blood"},{"issue":"1","key":"6524_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-024-01139-y","volume":"14","author":"AJ Devasia","year":"2024","unstructured":"Devasia AJ, Chari A, Lancman G (2024) Bispecific antibodies in the treatment of multiple myeloma. Blood Cancer J 14(1):1\u201317","journal-title":"Blood Cancer J"},{"issue":"1","key":"6524_CR66","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1182\/bloodadvances.2023011658","volume":"8","author":"KA Frerichs","year":"2024","unstructured":"Frerichs KA, Verkleij CPM, Mateos MV, Martin TG, Rodriguez C, Nooka A et al (2024) Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation. Blood Adv 8(1):194\u2013206","journal-title":"Blood Adv"},{"issue":"1","key":"6524_CR67","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","volume":"13","author":"N Raje","year":"2023","unstructured":"Raje N, Anderson K, Einsele H, Efebera Y, Gay F, Hammond SP et al (2023) Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel. Blood Cancer J 13(1):116","journal-title":"Blood Cancer J"},{"issue":"6","key":"6524_CR68","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","volume":"4","author":"G Lancman","year":"2023","unstructured":"Lancman G, Parsa K, Kotlarz K, Avery L, Lurie A, Lieberman-Cribbin A et al (2023) IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies. Blood Cancer Discov 4(6):440\u2013451","journal-title":"Blood Cancer Discov"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06524-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06524-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06524-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T06:02:57Z","timestamp":1761285777000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06524-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":68,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["6524"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06524-6","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"10 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Funding\n                      .","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This project is funded by the National Research Council of Thailand (NRCT): High-Potential Research Team Grant Program (N42A680423).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The academic endeavours of Thailand Hub of Talents in Cancer Immunotherapy (TTCI) receive support from the National Research Council of Thailand (N34E670096).","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"NH and MST were supported by the Second Century Fund (C2F), Chulalongkorn University, Bangkok, Thailand.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}